Article Details
Retrieved on: 2022-12-07 16:58:08
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The cardiovascular outcomes trial is a major test for Esperion, which has struggled to sell its drug since winning U.S. approval in 2020.
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here